Impact of systemic treatments for advanced thyroid cancer on the adrenal cortex
European Thyroid Journal · 2022
DOI: 10.1530/etj-23-0246 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Thyroid Journal, 2022. Verfasst von Carla Colombo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Endocrine Oncology Unit, Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy. Hauptthemen laut MEDLINE: Adrenal Cortex, Piperidines, Thyroid Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Fatigue is a frequent adverse event during systemic treatments for advanced thyroid cancer, often leading to reduction, interruption, or discontinuation. We were the first group to demonstrate a correlation between fatigue and primary adrenal insufficiency (PAI).
Aim
The objective was to assess the entire adrenal function in patients on systemic treatments.
Methods
ACTH, cortisol and all the hormones produced by the adrenal gland were evaluated monthly in 36 patients (25 on lenvatinib, six on vandetanib, and five on selpercatinib). ACTH stimulation tests were performed in 26 cases.
Results
After a median treatment period of 7 months, we observed an increase in ACTH values in 80–100% of patients and an impaired cortisol response to the ACTH test in 19% of cases. Additionally, dehydroepiandrosterone sulphate, ∆-4-androstenedione and 17-OH progesterone levels were below the median of normal values in the majority of patients regardless of the drug used. Testosterone in females and oestradiol in males were below the median of normal values in the majority of patients on lenvatinib and vandetanib. Finally, aldosterone was below the median of the normal values in most cases, whilst renin levels were normal. Metanephrines and normetanephrines were always within the normal range. Replacement therapy with cortisone acetate improved fatigue in 14/17 (82%) patients with PAI.
Conclusion
Our data confirm that systemic treatments for advanced thyroid cancer can lead to impaired cortisol secretion. A reduction in the other hormones secreted by the adrenal cortex has been first reported and should be considered in the more appropriate management of these fragile patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrine Oncology Unit, Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy.
- Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
- Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy.
ORCID-Profile: Laura Fugazzola
Zitieren
APA
Colombo, C., Ceruti, D., Succi, M., De Leo, S., Trevisan, M., Moneta, C., & Fugazzola, L. (2022). Impact of systemic treatments for advanced thyroid cancer on the adrenal cortex. European Thyroid Journal. https://doi.org/10.1530/etj-23-0246
Vancouver
Colombo C, Ceruti D, Succi M, De Leo S, Trevisan M, Moneta C, et al. Impact of systemic treatments for advanced thyroid cancer on the adrenal cortex. European Thyroid Journal. 2022. doi:10.1530/etj-23-0246
BibTeX
@article{Colombo2022,
author = {Colombo, Carla and Ceruti, Daniele and Succi, Massimiliano and De Leo, Simone and Trevisan, Matteo and Moneta, Claudia and Fugazzola, Laura},
title = {Impact of systemic treatments for advanced thyroid cancer on the adrenal cortex},
journal = {European Thyroid Journal},
year = {2022},
doi = {10.1530/etj-23-0246}
}
EUVIMED